IMMUNOGENIC AGENTS AGAINST BURKHOLDERIA PSEUDOMALLEI AND/OR BURKHOLDERIA MALLEI, COMPRISING LIPOPOLYSACCHARIDE, CAPSULAR POLYSACCHARIDE AND/OR PROTEINS FROM BURKHOLDERIA PSEUDOMALLEI

• US 20110236423A1
• Filed: 06/06/2011
• Published: 09/29/2011
• Est. Priority Date: 09/30/2005
• Status: Active Grant

• Current Assignee: Secretary of State For Defence
• Original Assignee: Secretary of State For Defence
• Inventors: Titball, Richard William, Healey, Gareth David, Nelson, Michelle, Sarkar-Tyson, Mitali, Elvin, Stephen John, Atkins, Timothy Philip, Eyles, James Edward, Smither, Sophie Jane, Williamson, Ethel Diane
• Granted Patent: US 8,425,913 B2
• Time in Patent Office: Days
• US Class Current: 424/234.1
• CPC Class Codes: A61K 39/104 Pseudomonadales, e.g. Pseudomonas
• CPC Class Codes: A61P 31/04 Antibacterial agents

Abstract

An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection by Burkholderia pseudomallei and/or Burkholderia mallei.

Claims

1. An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal.

2. The immunogenic agent of claim 1 which is a killed strain of Burkholderia pseudomallei.

3. The immunogenic agent of claim 2 wherein the strain is one which includes a capsular polysaccharide.

4. The immunogenic agent of claim 2 which is a heat-killed strain.

5. The immunogenic agent of claim 2 which is a killed version of a strain which has an atypical LPS serotype (OPSII).

6. The immunogenic agent of claim 1 which is a combination of Burkholderia pseudomallei components comprising at least two members of the group selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) an immunogenic protein of Burkholderia pseudomallei or an immunogenic variant thereof, or an immunogenic fragment of either of these, or a nucleic acid which expresses said immunogenic protein, variant or fragment in a host animal.

7. The immunogenic agent of claim 6 which comprises (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) an immunogenic protein of Burkholderia pseudomallei or an immunogenic variant thereof, or an immunogenic fragment of either of these, or a nucleic acid which expresses said immunogenic protein, variant or fragment in a host animal.

8. The immunogenic agent of claim 7 wherein component (i) comprises an OPSI and an OPSII B. pseudomallei lipopolysaccharide.

9. The immunogenic agent of claim 6 which includes component (iii), and where component (iii) is one or more immunogenic proteins of Burkholderia pseudomallei or an immunogenic variant thereof, or an immunogenic fragment of either of these.

10. The immunogenic agent of claim 9 wherein component (iii) comprises one or more immunogenic proteins of Burkholderia pseudomallei.

11. The immunogenic agent of claim 6 wherein the immunogenic protein of component (iii) is a surface protein of B. pseudomallei.

12. A pharmaceutical composition comprising the immunogenic reagent of claim 1, in combination with a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 12 further comprising an adjuvant.

14. The pharmaceutical composition of claim 13 wherein the adjuvant is a moiety which activates antigen-presenting cells.

15. The pharmaceutical composition of claim 14 wherein the moiety is one which activates dendritic cells.

16. The pharmaceutical composition of claim 15 wherein the said moiety is a Toll-like receptor ligand.

17. The pharmaceutical composition of claim 14 wherein said moiety is a CpG oligonucleotide.

18. A composition comprising the immunogenic agent of claim 1 and antigen-presenting cells.

19. The composition of claim 18 wherein the antigen-presenting cells are dendritic cells.

20. The composition of claim 18 further comprising an adjuvant capable of stimulating antigen-presenting cells.

21. The composition of claim 20 wherein the adjuvant is a CpG oligonucleotide.

25. A method of preventing or treating infection by Burkholderia pseudomallei and/or Burkholderia mallei, which method comprises administering to an animal the immunogenic agent of claim 1.

22-24. -24. (canceled)

26-29. -29. (canceled)